Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease

Key Points

• Interstitial lung disease is a significant adverse event associated with certain anticancer drugs, indicating potential genetic links.
• The analysis emphasizes pharmacovigilance as a crucial method for understanding drug safety and identifying genetic targets.
• Results from FDA data reveal how genetic target prediction can improve monitoring of adverse events for safer treatments.
• Findings suggest the need for enhanced pharmacovigilance efforts in recognizing and preventing drug-induced lung diseases.